A two-drug regimen for antiretroviral therapy

Lancet. 2019 Jan 12;393(10167):106-108. doi: 10.1016/S0140-6736(18)32783-1. Epub 2018 Nov 9.

Authors

Arne Kroidl¹, Joseph Eberle²

Affiliations

¹ Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich, Munich 80802, Germany. Electronic address: akroidl@lrz.uni-muenchen.de.
² Max von Pettenkofer Institute & Gene Center, Virology, National Reference Center for Retroviruses, Medical Center of the University of Munich, Munich, Germany.

PMID: 30420122
DOI: 10.1016/S0140-6736(18)32783-1

No abstract available

Publication types

Comment

MeSH terms

Adult
Double-Blind Method
Emtricitabine*
HIV Infections
HIV-1
Heterocyclic Compounds, 3-Ring
Humans
Lamivudine*
Oxazines
Piperazines
Pyridones
Tenofovir

Substances

Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
Lamivudine
Tenofovir
dolutegravir
Emtricitabine